John Butcher, MD
Family Medicine · Jacksonville, FLNPI 1275510810
Payments from drug & device makers
Across 171 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$608
- Novo Nordisk$554
- AstraZeneca$439
- Phathom Pharmaceuticals, Inc.$168
- Abbott$157
- Amarin Pharma, Inc.$114
- plus $800 from 19 others
What the payments were for
- Food & beverage$2,841100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 38 | $608 |
| Novo Nordisk | 45 | $554 |
| AstraZeneca | 27 | $439 |
| Phathom Pharmaceuticals, Inc. | 4 | $168 |
| Abbott | 4 | $157 |
| Amarin Pharma, Inc. | 7 | $114 |
| Lilly USA, LLC | 6 | $103 |
| AbbVie(2 entities) | 5 | $92 |
| Bayer | 4 | $79 |
| Antares Pharma, Inc. | 5 | $68 |
| GSK | 3 | $58 |
| Pfizer | 3 | $56 |
| Johnson & Johnson | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $45 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| Merck | 2 | $37 |
| Metuchen Pharmaceuticals | 2 | $30 |
| Hikma Pharmaceuticals USA | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Vivus LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $12 |
How this compares
$2,841 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $96,717 |
| EliquisApixaban | 44 | $43,973 |
| MounjaroTirzepatide | 36 | $41,012 |
| FarxigaDapagliflozin Propanediol | 37 | $39,150 |
| JanuviaSitagliptin Phosphate | 39 | $25,495 |
| MyrbetriqMirabegron | 29 | $25,245 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $24,992 |
| RybelsusSemaglutide | 15 | $24,757 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $23,010 |
| JardianceEmpagliflozin | 15 | $17,915 |
| WegovySemaglutide | 12 | $16,256 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $9,890 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,882 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,673 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $554 | $137,731112 claims |
| PfizerEliquis, Paxlovid | $56 | $46,64368 claims |
| AstraZenecaFarxiga, Symbicort | $439 | $41,80748 claims |
| Lilly USA, LLCMounjaro | $103 | $41,01236 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $58 | $40,85874 claims |
| MerckJanuvia | $37 | $25,49539 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $25,24529 claims |
| Boehringer IngelheimJardiance | $15 | $17,91515 claims |
| AbbVieSynthroid | $92 | $5,43155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Jacksonville
- Jeffry JacqmeinJacksonville$8.7M
- Herman DowneyJacksonville$4.1M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.